Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Jefferies Downgrades Marinus Pharmaceuticals (MRNS)
Fintel reports that on October 25, 2024, Jefferies downgraded their outlook for Marinus Pharmaceuticals (NasdaqGM:MRNS) from Buy to Hold. Analyst Price Forecast Suggests 2,829.05% Upside As of October 22,
Why Did Marinus Pharmaceuticals Inc (MRNS) Stock See 23.33% Surge in the Last 90 Days?
On Friday, Marinus Pharmaceuticals Inc (MRNS) stock saw a modest uptick, ending the day at $1.85 which represents a slight increase of $0.11 or 6.32% from the prior close of $1.74. The stock opened at $1.
Marinus (MRNS) was downgraded to a Hold Rating at JMP Securities
Marinus (MRNS – Research Report) received a Hold rating and price target from JMP Securities analyst Jason Butler today. The
TD Cowen Downgrades Marinus Pharmaceuticals (MRNS)
Fintel reports that on October 25, 2024, TD Cowen downgraded their outlook for Marinus Pharmaceuticals (NasdaqGM:MRNS) from Buy to Hold. Analyst Price Forecast Suggests 2,829.05% Upside As of October 22,
FiercePharma
2d
Marinus to trim workforce, weigh 'strategic alternatives' after another Ztalmy trial miss sends shares tumbling
The recent trial flop for Ztalmy, this time in tuberous sclerosis complex (TSC)-associated seizures, leaves the company in a ...
1d
on MSN
Marinus downgraded after setback to late-stage trial
Marinus Pharmaceuticals (MRNS) stock was downgraded at TD Cowen and Truist after a Phase 3 failure for lead asset, ganaxolone ...
2d
Marinus Pharmaceuticals' Oral Seizure Drug Disappoints In Late-Stage Study, Appoints Advisor To Explore Options
On Thursday, Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) stock plunged after the company revealed disappointing data from the ...
2d
Marinus Pharmaceutical Shares Plumb New Depths After Study Failure
Marinus Pharmaceuticals shares plunged nearly 80% to a new all-time low on Thursday after the pharmaceutical company said it is cutting jobs and exploring strategic options following the failure of ...
BioPharma Dive
1d
GSK invests $800M in manufacturing; Amgen sets small discount for Eylea biosimilar
The British pharma is making what it calls its largest U.S. manufacturing investment. Elsewhere, AbbVie expanded a ...
MarketBeat on MSN
12d
Will Marinus Pharmaceuticals Be the Next Big Winner in Biotech?
Detailed price information for Marinus Pharma CS (MRNS-Q) from The Globe and Mail including charting and trades.
Monthly Prescribing Reference
2d
Ganaxolone Misses Endpoint in Tuberous Sclerosis Complex Trial
Ganaxolone is a neuroactive steroid GABAA receptor positive modulator that targets the brain’s anti-seizure response.
1d
Marinus Pharmaceuticals price target lowered to $4 from $13 at Cantor Fitzgerald
Cantor Fitzgerald analyst Charles Duncan lowered the firm’s price target on Marinus Pharmaceuticals (MRNS) to $4 from $13 and keeps an ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback